Prof. Dr. med. Christian Hagemeier

University Education

• 1980-1982 Medicine, University of Münster
• 1983-1984 M.D., Department of Biochemistry, Universität Münster
• 1984-1985 University of Cambridge and Oxford, UK
• 1986 University of Newcastle, Australia and Universität Münster, state examination

Professional Experience (selection)

• 1989-1992 Ph.D., University of Cambridge & Medical Research Council (MRC), Molecular Medicine Unit, UK
• 1992-1994 Postdoctoral research fellow, University of Cambridge, Cancer Research, UK
• 1995-2002 Head of DFG Clinical Research Group, Children’s Hospital, Charité
• To date      Head of the Laboratory of Pediatric Molecular Biology and Co-Head, Laboratory of Functional Genomics, Charité 

Research Fields

• i)    Molecular Oncology
• ii)   Epigenetics
• iii)  Cell cycle control 

Most important Awards, Grants or Scientific Achievements

• Head of DFG Clinical Research Group, Speaker of NGFN consortium Functional Genomics of Acute Leukemias

Selected References

• Bogdanow, B., Schmidt, M., Weisbach, H., Gruska, I., Vetter, B., Imami, K., Ostermann, E., Brune, W., Selbach, M., Hagemeier, C., & Wiebusch, L. (2020). Cross-regulation of viral kinases with cyclin A secures shutoff of host DNA synthesis. Nature communications, 11(1), 4845.
• Schiesser, S., Hackner, B., Pfaffeneder, T., Müller, M., Hagemeier, C., Truss, M., & Carell, T. (2012). Mechanism and stem-cell activity of 5-carboxycytosine decarboxylation determined by isotope tracing. Angewandte Chemie (International ed. in English), 51(26), 6516–6520.
• Pfaffeneder, T., Hackner, B., Truss, M., Münzel, M., Müller, M., Deiml, C. A., Hagemeier, C., & Carell, T. (2011). The discovery of 5-formylcytosine in embryonic stem cell DNA. Angewandte Chemie (International ed. in English), 50(31), 7008–7012.
• Rhein, P., Mitlohner, R., Basso, G., Gaipa, G., Dworzak, M. N., Kirschner-Schwabe, R., Hagemeier, C., Stanulla, M., Schrappe, M., Ludwig, W. D., Karawajew, L., & Ratei, R. (2010). CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia. Blood, 115(18), 3763–3771.
• Pohlers, M., Truss, M., Frede, U., Scholz, A., Strehle, M., Kuban, R. J., Hoffmann, B., Morkel, M., Birchmeier, C., & Hagemeier, C. (2005). A role for E2F6 in the restriction of male-germ-cell-specific gene expression. Current biology : CB, 15(11), 1051–1057.
• Hof, J., Krentz, S., van Schewick, C., Körner, G., Shalapour, S., Rhein, P., Karawajew, L., Ludwig, W. D., Seeger, K., Henze, G., von Stackelberg, A., Hagemeier, C., Eckert, C., & Kirschner-Schwabe, R. (2011). Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(23), 3185–3193.
• Hof, J., Krentz, S., van Schewick, C., Körner, G., Shalapour, S., Rhein, P., Karawajew, L., Ludwig, W. D., Seeger, K., Henze, G., von Stackelberg, A., Hagemeier, C., Eckert, C., & Kirschner-Schwabe, R. (2011) "Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia." Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(23), 3185–3193.
• Wiebusch, L., & Hagemeier, C. (2010). p53- and p21-dependent premature APC/C-Cdh1 activation in G2 is part of the long-term response to genotoxic stress. Oncogene, 29(24), 3477–3489.
• Młynarczuk-Biały, I., Roeckmann, H., Kuckelkorn, U., Schmidt, B., Umbreen, S., Gołab, J., Ludwig, A., Montag, C., Wiebusch, L., Hagemeier, C., Schadendorf, D., Kloetzel, P.M., Seifert, U.(2006) "Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells." Cancer Res. 2006 Aug 1;66(15):7598-605.
• Morkel, M., Wenkel, J., Bannister, A. J., Kouzarides, T., & Hagemeier, C. (1997) "An E2F-like repressor of transcription." Nature, 390(6660), 567–568.